Table 2.

Summary of studies on liver organoid applications in regenerative medicine.

Author	Approach	Disease Mouse Model	Reconstitution	Follow Up	Reference
Huch et al.	Bile-duct derived organoids from Lgr5+ stem cells	Fumarylacetoacetate hydrolase (FAH)−/− mutant mice (model for Tyrosinemia type I liver disease)	0.1% of total liver volume	60–90 days	[112]
Huch et al.	EpCAM+ ductal cells from human liver biopsies induced to differentiate in hepatocytes and to form organoids	Balb/c nude mice treated with CCl4-retrorsine to induce acute liver damage	50–100 ng/mL of blood human albumin levels	120 days	[144]
Hu et al.	3D organoids from mouse and human primary hepatocytes	Fah−/− NOD Rag1−/− Il2rg−/− (FNRG) mice (model of tyrosinemia type I)	200 µg/mL on average of blood human albumin levels	90 days	[145]
Rashidi et al.	Organoid from iPSC-derived hepatocytes	Fumarylacetoacetate hydrolase (FAH)−/− mutant mice (model for Tyrosinemia type I liver disease) and Fah−/− NOD Rag1−/− Il2rg−/− (FNRG) mice (model tyrosinemia type I)	Detectable levels of human albumin	14 days	[146]
Blackford et al.	iPSC-derived hepatocytes generated with a cGMP compliant method was established to generate and seeded on a 3D poly-ethylene glycol-diacrylate scaffold to generate an organoid	Immune competent (C57BL/6 and Crl:CD1) and immune deficient (Rag2γ) mice	Detectable levels of human albumin	12 days	[147]